MCID: ACT075
MIFTS: 56

Acute Myocardial Infarction

Categories: Cardiovascular diseases, Genetic diseases

Aliases & Classifications for Acute Myocardial Infarction

MalaCards integrated aliases for Acute Myocardial Infarction:

Name: Acute Myocardial Infarction 12 54 15 17 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:9408
ICD9CM 34 410 410.9 410.90
NCIt 49 C35204
SNOMED-CT 67 57054005
ICD10 32 I21 I21.9
UMLS 71 C0155626

Summaries for Acute Myocardial Infarction

MalaCards based summary : Acute Myocardial Infarction is related to acute anterolateral myocardial infarction and cardiac rupture, and has symptoms including angina pectoris and chest pain. An important gene associated with Acute Myocardial Infarction is MIR499A (MicroRNA 499a). The drugs Pravastatin and Insulin glargine have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and testes, and related phenotype is cardiovascular system.

Related Diseases for Acute Myocardial Infarction

Diseases in the Myocardial Infarction family:

Myocardial Infarction 2 Posterior Myocardial Infarction
Acute Myocardial Infarction

Diseases related to Acute Myocardial Infarction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 882)
# Related Disease Score Top Affiliating Genes
1 acute anterolateral myocardial infarction 33.9 PIK3C2A ACE
2 cardiac rupture 33.9 PLAT CRP
3 myocardial infarction 33.6 TNNT2 TNNI3 SELP PLAT PIK3C2A NPPB
4 cardiogenic shock 33.4 PLAT NPPB CRP
5 coronary thrombosis 33.3 SELP PLAT F3
6 ischemia 32.8 SELP PLAT PIK3C2A NPPB MB ACE
7 angina pectoris 32.8 TNNI3 PLAT PIK3C2A NPPB MB F3
8 intermediate coronary syndrome 32.7 TNNT2 TNNI3 SELP PLAT PIK3C2A MB
9 inferior myocardial infarction 32.7 PLAT PIK3C2A NPPB
10 cardiac arrest 32.6 TNNT2 SELP PIK3C2A NPPB FABP3 ACE
11 mitral valve insufficiency 32.5 TNNT2 TNNI3 NPPB CRP ACE
12 left bundle branch hemiblock 32.5 TNNT2 TNNI3 PIK3C2A NPPB CRP ACE
13 coronary stenosis 32.5 TNNI3 PIK3C2A NPPB CRP ACE
14 anterolateral myocardial infarction 32.5 PLAT NPPB ACE
15 pulmonary edema 32.4 TNNT2 TNNI3 PIK3C2A NPPB CRP ACE
16 pericarditis 32.4 TNNT2 TNNI3 NPPB CRP ACE
17 myocarditis 32.4 TNNI3 PIK3C2A NPPB MB ACE
18 arteries, anomalies of 32.3 TNNT2 TNNI3 SELP PLAT NPPB F3
19 right bundle branch block 32.3 TNNI3 NPPB ACE
20 atrial standstill 1 32.3 TNNT2 TNNI3 NPPB ACE
21 coronary artery anomaly 32.3 TNNT2 TNNI3 SELP PLAT PIK3C2A NPPB
22 coronary artery vasospasm 32.3 TNNI3 PIK3C2A CRP ACE
23 atrial fibrillation 32.3 TNNT2 TNNI3 SELP PLAT NPPB F3
24 cerebrovascular disease 32.2 SELP PLAT NPPB CRP ACE
25 vascular disease 32.2 SELP PLAT NPPB F3 CRP ACE
26 pericardial effusion 32.2 TNNI3 PIK3C2A NPPB F3 CRP ACE
27 peripheral vascular disease 32.2 SELP PLAT F3 CRP ACE
28 congestive heart failure 32.1 TNNT2 TNNI3 PIK3C2A NPPB FABP3 CRP
29 cardiac tamponade 32.1 TNNI3 PLAT PIK3C2A NPPB F3 CRP
30 atrioventricular block 32.1 TNNI3 PIK3C2A NPPB MHRT ACE
31 chronic kidney disease 32.1 TNNT2 TNNI3 NPPB CRP ACE
32 endocarditis 32.1 TNNI3 PLAT PIK3C2A CRP
33 antiphospholipid syndrome 32.1 SELP PLAT F3 CRP
34 pulmonary embolism 32.1 TNNT2 TNNI3 PLAT NPPB MB FABP3
35 respiratory failure 32.0 PIK3C2A NPPB F3 CRP ACE
36 acute myocarditis 32.0 TNNI3 NPPB CRP ACE
37 anteroseptal myocardial infarction 32.0 PIK3C2A MB
38 end stage renal failure 32.0 SELP NPPB CRP ACE
39 sleep apnea 32.0 SELP NPPB CRP ACE
40 posterior myocardial infarction 32.0 PLAT PIK3C2A MB
41 myocardial stunning 32.0 TNNT2 TNNI3 ACE
42 purpura 31.9 SELP F3 CRP ACE
43 coronary heart disease 1 31.9 SELP PLAT NPPB CRP CDKN2B-AS1 ACE
44 thrombocytopenia 31.9 SELP PLAT PIK3C2A F3 CRP
45 pulmonary disease, chronic obstructive 31.8 NPPB MB CRP ACE
46 infective endocarditis 31.8 TNNT2 TNNI3 CRP
47 arteriosclerosis 31.8 SELP F3 CRP ACE
48 deficiency anemia 31.7 SELP PIK3C2A MB CRP ACE
49 disseminated intravascular coagulation 31.7 PLAT PIK3C2A MB F3 CRP
50 patent foramen ovale 31.7 TNNT2 TNNI3 PLAT NPPB F3 CRP

Comorbidity relations with Acute Myocardial Infarction via Phenotypic Disease Network (PDN): (show all 19)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Aortic Valve Disease 1
Cardiac Arrest Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Kidney Disease Mitral Valve Disease
Peripheral Vascular Disease Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Acute Myocardial Infarction:



Diseases related to Acute Myocardial Infarction

Symptoms & Phenotypes for Acute Myocardial Infarction

UMLS symptoms related to Acute Myocardial Infarction:


angina pectoris, chest pain

MGI Mouse Phenotypes related to Acute Myocardial Infarction:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.32 ACE CRP F3 FABP3 MB PIK3C2A

Drugs & Therapeutics for Acute Myocardial Infarction

Drugs for Acute Myocardial Infarction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 511)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pravastatin Approved Phase 4 81093-37-0 54687
2
Insulin glargine Approved Phase 4 160337-95-1
3
Etanercept Approved, Investigational Phase 4 185243-69-0
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
6
Eplerenone Approved Phase 4 107724-20-9 150310 443872
7
Streptokinase Approved, Investigational Phase 4 9002-01-1
8
Verapamil Approved Phase 4 52-53-9 2520
9
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
10
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
11
Liraglutide Approved Phase 4 204656-20-2 44147092
12
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
13
Ethanol Approved Phase 4 64-17-5 702
14
Edaravone Approved, Investigational Phase 4 89-25-8 70335
15
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
16
Reteplase Approved, Investigational Phase 4 133652-38-7 65820
17
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
18
Histamine Approved, Investigational Phase 4 51-45-6 774
19
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
20
Famotidine Approved Phase 4 76824-35-6 3325
21 Apricot Approved Phase 4
22
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
23
Phylloquinone Approved, Investigational Phase 4 84-80-0
24
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
25
Aminophylline Approved Phase 4 317-34-0 9433
26
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
27
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
28
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
29
Caffeine Approved Phase 4 58-08-2 2519
30
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
31
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
32
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
33
Ezetimibe Approved Phase 4 163222-33-1 150311
34
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
35
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
36
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
37
Hydralazine Approved Phase 4 86-54-4 3637
38
Desflurane Approved Phase 4 57041-67-5 42113
39
Haloperidol Approved Phase 4 52-86-8 3559
40
Phenindione Approved, Investigational Phase 4 83-12-5 4760
41 fluindione Approved, Investigational Phase 4 957-56-2
42
Triflusal Approved, Investigational Phase 4 322-79-2
43
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
44
Chromium Approved Phase 4 7440-47-3 27668
45
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
46
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
47
Enalaprilat Approved Phase 4 76420-72-9 6917719
48
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
49
Sodium citrate Approved, Investigational Phase 4 68-04-2
50
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083

Interventional clinical trials:

(show top 50) (show all 1296)
# Name Status NCT ID Phase Drugs
1 Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI) Unknown status NCT00423020 Phase 4 Erythropoietin
2 Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study That Evaluates the Effects of Pravastatin for Acute Myocardial Infarction With LDL-Cholesterol Levels of 70-129 mg/dl Unknown status NCT00688922 Phase 4 Pravastatin
3 Randomized Study Of Sirolimus Eluting Stent Vs Conventional Stent In Acute Myocardial Infarction Acronym SESAMI Unknown status NCT00288210 Phase 4
4 Treating Acute MI Patients With Aggrastat on Their Way to Hospital Unknown status NCT00300833 Phase 4 Tirofiban
5 Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction Unknown status NCT01156662 Phase 4
6 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
7 Study of Anti-inflammatory Treatment With Colchicine in the Acute Phase of ST-elevation Myocardial Infarction to Reduce Infarct Size Unknown status NCT01936285 Phase 4 Colchicine 2 mg loading dose; 0.5 mg bid for 5 days;Placebo
8 Imaging of Inflammation in the Postischemic Myocardium: Effect of Anti-inflammatory Treatment With Colchicine Unknown status NCT02281305 Phase 4 Colchicine
9 Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction) Unknown status NCT02428374 Phase 4 Rosuvastatin plus clopidogrel;Rosuvastatin plus ticagrelor;Simvastatin plus clopidogrel;Simvastatin plus ticagrelor
10 Dissecting the Role of Distal Embolization of Athero-thrombotic Material in Primary PCI: the ThrombOticBurden and mIcrovAscularobStruction (TOBIAS) Study. Unknown status NCT01914055 Phase 4
11 Effect of Vitamin C Infusion on Coronary Reperfusion Indexes Unknown status NCT01090895 Phase 4 Vitamin C;Placebo
12 A Randomized Clinical Trial Comparing Primary PCI and Post-thrombolysis PCI as Reperfusion Strategies in Patients With ST Segment Elevation Acute Myocardial Infarction Unknown status NCT02268669 Phase 4
13 Evaluation of Neointimal Coverage of Everolimus-Eluting Stent and Bare-metal Stent After Implantation in STEMI Patients by Optical Coherence Tomography Unknown status NCT01875835 Phase 4
14 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
15 Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study (TAPAS II) Unknown status NCT01013038 Phase 4
16 Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT Unknown status NCT02233790 Phase 4 Ticagrelor;Clopidogrel
17 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
18 Phase 4 Study of Primary Angioplasty Combined Distal Injection of Abciximab to Thrombus and Aspiration With Catheter Unknown status NCT01383785 Phase 4
19 The Safety and Efficacy of Etanercept in Treating Patient With Acute ST Segment Elevated Myocardial Infarction Unknown status NCT01372930 Phase 4 Etanercept;saline
20 Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI Unknown status NCT00976092 Phase 4 Prasugrel;Bivalirudin;Clopidogrel;Heparin
21 Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Administered With the Single High-Dose Bolus Versus Abciximab and Sirolimus Eluting Stent Versus Bare Metal Stent in Acute Myocardial Infarction - MULTI-STRATEGY Trial Unknown status NCT00229515 Phase 4
22 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
23 Microvascular Reperfusion Utilizing Sonothrombolysis in Acute Myocardial Infarction (MRUSMI TRIAL) Unknown status NCT02170103 Phase 4 Microbubbles
24 Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study) Unknown status NCT02792712 Phase 4 Ticagrelor;Clopidogrel
25 Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data Unknown status NCT01035528 Phase 4 insulin glargine;metformin
26 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
27 Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome Unknown status NCT02049229 Phase 4
28 Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
29 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
30 Phase 4 Study of the Effect of Human Recombinant Erythropoietin at the Time of Reperfusion in Patients With Acute Myocardial Infarction Completed NCT00882466 Phase 4 human recombinant erythropoietin
31 Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction Completed NCT02627950 Phase 4 Morphinhydrochloricum;Metoclopramide;Ticagrelor;Isotonic sodium chloride
32 Comparison of Administration of Tirofiban in the Ambulance or in the Cathlab in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty Completed NCT00538317 Phase 4 tirofiban;tirofiban
33 Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction Completed NCT02808767 Phase 4 Prasugrel;Ticagrelor
34 Thrombus Aspiration Before Standard Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction. Completed NCT00257153 Phase 4
35 Prospective Randomized Multicenter Study Comparing Immediate Multivessel Revascularization by PCI Versus Culprit Lesion PCI With Staged Non-culprit Lesion Revascularization in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Completed NCT01927549 Phase 4
36 Southwest German Interventional Study in Acute Myocardial Infarction III Completed NCT01124890 Phase 4
37 Phase 4 Study of Application of Intracoronary Low Dose Streptokinase Complementary to Standard Percutaneous Coronary Intervention in Patients With ST Elevation Acute Myocardial Infarction: Effect of Adjunctive Intracoronary Streptokinase on Late Term Left Ventricular Infarct Size and Volumes in Patients With Acute Myocardial Infarction Completed NCT00627809 Phase 4 Streptokinase
38 A Multi-center, Randomized, Controlled Study of Mechanical Left Ventricular Unloading With Counterpulsation to Reduce Infarct Size Pre-PCI for Acute Myocardial Infarction - CRISP AMI Completed NCT00833612 Phase 4
39 The Effects of Facilitated Percutaeous Coronary Intervention Compared to Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Acute Myocardial Infarction Completed NCT00611169 Phase 4 tirofiban
40 Randomized Clinical Study of Intraaortic Balloon Pump Use in Cardiogenic Shock Complicating Acute Myocardial Infarction Completed NCT00491036 Phase 4
41 Bivalirudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin Undergoing Angioplasty (BRIGHT):a Randomised Controlled Trial Completed NCT01696110 Phase 4 Bivalirudin;heparin;heparin plus tirofiban
42 AIR-MI: Assessment of Ischemia and Remodeling Following Acute Myocardial Infarction Completed NCT00162331 Phase 4 Technetium Tc99m Sestamibi
43 IRIS - Immediate Risk-stratification Improves Survival - Joint Study of the German University Hospitals and German Society of Leading Cardiological Hospital Physicians (ALKK) Completed NCT00157768 Phase 4
44 Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure. Completed NCT00324766 Phase 4 levosimendan;placebo,
45 Reversal of No-reflow/Slow-flow During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction--a Prospective Randomized Study Comparing Intracoronary Infusion of Diltiazem, Verapamil and Nitroglycerin Completed NCT00712894 Phase 4 Diltiazem;Verapamil;Nitroglycerin
46 Phase 4 Study of Atorvastatin 10mg vs. 40mg in Follow-up CFR in AMI Patients Completed NCT00536887 Phase 4 atorvastatin
47 Effects of Early Statin Treatment on Symptomatic Heart Failure and Ischemic Events After Acute Myocardial Infarction. The MUSASHI-AMI: A Multicenter Randomized Controlled Trial Completed NCT00128024 Phase 4 lipid-lowering treatment
48 A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study Completed NCT00986050 Phase 4 Abciximab
49 Randomized Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction Completed NCT02544594 Phase 4
50 The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Primary Angioplasty for Acute Myocardial Infarction. The CONTRAST-AMI Study. Completed NCT00827788 Phase 4 Iodixanol;Iopromide

Search NIH Clinical Center for Acute Myocardial Infarction

Genetic Tests for Acute Myocardial Infarction

Anatomical Context for Acute Myocardial Infarction

MalaCards organs/tissues related to Acute Myocardial Infarction:

40
Heart, Bone, Testes, Endothelial, Bone Marrow, Kidney, Brain

Publications for Acute Myocardial Infarction

Articles related to Acute Myocardial Infarction:

(show top 50) (show all 30463)
# Title Authors PMID Year
1
Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. 46
20921333 2010
2
Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. 54 61
20378999 2010
3
Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction. 54 61
19662337 2010
4
Activation of peripheral blood mononuclear cells and extracellular matrix and inflammatory gene profile in acute myocardial infarction. 54 61
20388121 2010
5
Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. 54 61
20435200 2010
6
Left ventricular function and C-reactive protein levels in acute myocardial infarction. 54 61
20346306 2010
7
Point-of-care test of heart-type fatty acid-binding protein for the diagnosis of early acute myocardial infarction. 54 61
20140003 2010
8
[The significance of the changes in expressions of heat shock protein 70 and heme oxygenase-1 in the myocardium in patients died suddenly due to acute myocardial infarction]. 54 61
20170613 2010
9
Circulating p53 and cytochrome c levels in acute myocardial infarction patients. 54 61
19551350 2010
10
Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. 54 61
20102882 2010
11
Noninvasive assessment of left ventricular filling pressure after acute myocardial infarction: a prospective study of the relative prognostic utility of clinical assessment, echocardiography, and B-type natriuretic peptide. 54 61
20102866 2010
12
Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction. 54 61
19809306 2009
13
Admission creatine kinase as a prognostic marker in acute myocardial infarction. 54 61
20201171 2009
14
The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. 54 61
19410278 2009
15
TNF-alpha/IL-10 ratio and C-reactive protein as markers of the inflammatory response in CAD-prone North Indian patients with acute myocardial infarction. 54 61
19576194 2009
16
Increased expression of TF on monocytes, but decreased numbers of TF bearing microparticles in blood from patients with acute myocardial infarction. 54 61
19558505 2009
17
The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. 54 61
19520708 2009
18
[Correlation between serum MMP-2 and MMP-9 in patients with acute myocardial infarction before and after PCI]. 54 61
19664397 2009
19
Conjugation of biomolecules with magnetic protein microspheres for the assay of early biomarkers associated with acute myocardial infarction. 54 61
19555077 2009
20
Carboxylated magnetic microbead-assisted fluoroimmunoassay for early biomarkers of acute myocardial infarction. 54 61
19398193 2009
21
The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. 54 61
19637097 2009
22
Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. 54 61
19570241 2009
23
Association of C-reactive protein and HIV infection with acute myocardial infarction. 54 61
19387353 2009
24
The impact of admission C-reactive protein levels on the development of no-reflow phenomenon after primary PCI in patients with acute myocardial infarction: the role of inflammation. 54 61
18579226 2009
25
[Study of association of platelet endothelial cell adhesion molecule-1 gene polymorphism with acute myocardial infarction]. 54 61
19570335 2009
26
[An angiographic trial to evaluate the efficacy and safety of tenecteplase in Chinese patients with acute myocardial infarction]. 54 61
19927632 2009
27
Expressions of eNOS3 and Ve-cadherin in microvascular endothelium at 7-day of reperfused acute myocardial infarction. 54 61
19519369 2009
28
Superparamagnetic microsphere-assisted fluoroimmunoassay for rapid assessment of acute myocardial infarction. 54 61
19394809 2009
29
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. 54 61
19346228 2009
30
Human heart-type fatty acid-binding protein for on-site diagnosis of early acute myocardial infarction. 54 61
18571749 2009
31
Levels of serum deoxyribonuclease I activity on admission in patients with acute myocardial infarction can be useful in predicting left ventricular enlargement due to remodeling. 54 61
19304122 2009
32
[Coronary flow and hemorrhagic complications after alteplase and streptokinase administration in patients with acute myocardial infarction]. 54 61
19341228 2009
33
[The relationship between plasma BNP level and the left ventricular dysfunction parameters in patients with acute myocardial infarction and it's value in diagonosing heart failure.]. 54 61
19781144 2009
34
Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril. 54 61
18190989 2009
35
Factors associated with C-reactive protein at the early stage of acute myocardial infarction in men. 54 61
19130414 2009
36
The relationship of plasminogen activator inhibitor-1 levels to the ST deviation pattern of acute myocardial infarction. 54 61
18580060 2009
37
Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. 54 61
18997620 2009
38
Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission. 54 61
19246845 2009
39
Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction. 54 61
18038115 2008
40
[Plasma tissue factor and tissue factor pathway inhibitor levels in acute myocardial infarction patients with no-reflow during percutaneous coronary intervention]. 54 61
19102916 2008
41
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. 46
18723672 2008
42
[Comparative effect of streptokinase and alteplase on electrocardiogram and angiogram signs of myocardial reperfusion in ST segment elevation acute myocardial infarction]. 54 61
19069338 2008
43
Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. 54 61
18810578 2008
44
Impact of plaque rupture and elevated C-reactive protein on clinical outcome in patients with acute myocardial infarction: an intravascular ultrasound study. 54 61
18762670 2008
45
Relationship of sustained brain natriuretic peptide release after reperfused acute myocardial infarction with gated SPECT infarct measurements and its connection with collagen turnover and left ventricular remodeling. 54 61
18761267 2008
46
Value of blood adipose tissue hormones concentration--adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in 1-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial infarction. 54 61
18766137 2008
47
[Role of nuclear factor-KappaB in endothelial injury in acute myocardial infarction]. 54 61
18611340 2008
48
A close relationship between functional polymorphism in the promoter region of matrix metalloproteinase-9 and acute myocardial infarction. 54 61
17698228 2008
49
Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. 54 61
18490430 2008
50
Value of brain natriuretic peptide after acute myocardial infarction. 54 61
18524723 2008

Variations for Acute Myocardial Infarction

Copy number variations for Acute Myocardial Infarction from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 210497 6 30400000 36600000 Amplification C4B Acute myocardial infarction

Expression for Acute Myocardial Infarction

LifeMap Discovery
Genes differentially expressed in tissues of Acute Myocardial Infarction patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 EGR3 early growth response 3 Blood + 5.52 0.000
2 LOC286058 uncharacterized LOC286058 Blood + 4.73 0.000
3 CXCL8 chemokine (C-X-C motif) ligand 8 Blood + 3.51 0.004
4 LEP leptin Heart + 3.45 0.011
5 ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein Blood + 3.18 0.007
Search GEO for disease gene expression data for Acute Myocardial Infarction.

Pathways for Acute Myocardial Infarction

GO Terms for Acute Myocardial Infarction

Cellular components related to Acute Myocardial Infarction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 SELP PLAT NPPB MIR29A FABP3 F3
2 troponin complex GO:0005861 9.16 TNNT2 TNNI3
3 cardiac myofibril GO:0097512 8.96 TNNT2 TNNI3
4 cardiac Troponin complex GO:1990584 8.62 TNNT2 TNNI3

Biological processes related to Acute Myocardial Infarction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of muscle contraction GO:0006937 9.26 TNNT2 TNNI3
2 heart contraction GO:0060047 9.16 TNNI3 ACE
3 negative regulation of ATPase activity GO:0032780 8.96 TNNT2 TNNI3
4 transition between fast and slow fiber GO:0014883 8.62 MIR499A MIR208B

Molecular functions related to Acute Myocardial Infarction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 troponin C binding GO:0030172 8.62 TNNT2 TNNI3

Sources for Acute Myocardial Infarction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA